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IL-35 is critical in suppressing superantigenic Staphylococcus
aureus-driven inflammatory Th17 responses in human
nasopharynx-associated lymphoid tissue
Rong Xu1, Rebecca K. Shears1, Ravi Sharma2, Madhan Krishna2, Christopher Webb3, Richard Ali4, Xiaoqing Wei4, Aras Kadioglu1 and
Qibo Zhang 1
The human nasopharynx is frequently exposed to microbial pathogens, including superantigen-producing Staphylococcus aureus
(SAg-Sau), which activates potent pro-inflammatory T cell responses. However, cellular mechanisms that control SAg-Sau-driven
T cell activation are poorly understood. Using human nasopharynx-associated lymphoid tissue (NALT), we show that SAg-Sau drove
a strong Th17 activation, which was associated with an impaired CD4+ T cell-mediated immune regulation. This impairment of
immune control correlated with a significant downregulation of interleukin-35 (IL-35) expression in tonsillar CD4+ T cells by SAg-
Sau. Supplementing recombinant IL-35 suppressed SAg-Sau-activated Th17 responses, and this IL-35-mediated suppression
positively correlated with the level of Th17 activation. Interestingly, SAg-Sau stimulation induced Foxp3+ Treg expansion and
interleukin-10 (IL-10) production, which effectively suppressed the Th1 response, but failed to control the activation of Th17 cells.
Overall, our results reveal an aberrant T cell regulation on SAg-Sau-driven Th17 activation and identify IL-35 as a critical cytokine to
control superantigenic S.aureus-activated Th17 responses.
Mucosal Immunology (2020) 13:460–470; https://doi.org/10.1038/s41385-019-0246-1
INTRODUCTION
Staphylococcus aureus (Sau) is a commonly identified bacterial
colonizer of the nasopharyngeal mucosa in humans.1 Up to half of
the Sau isolates are known to be superantigenic, and produce
various superantigens, including toxic shock syndrome toxin
(TSST) and staphylococcal enterotoxins (SEA, SEB, SEC, SED, and
SEE).2,3 These superantigens are extremely potent in stimulating
poly-clonal T cell activation via cross-linking the MHC Class II of
antigen-presenting cells (APC) and T cell receptor Vβ chain, which
is not restricted to antigen specificity.4
Nasopharyngeal carriage of Sau increases the risk of invasive
infections such as pneumonia, endocarditis and bacteraemia.5
SAg-Sau infection could cause toxic shock through the release of
superantigens which elicit potent T cell activation and a “cytokine
storm”.6 Further, SAg-Sau colonization has been associated with a
range of inflammatory/autoimmune conditions, including asthma,
chronic rhinosinusitis, Wegener’s granulomatosis (WG) and multi-
ple sclerosis (MS).3,7–9
Nasopharynx-associated lymphoid tissues (NALT) are mucosal
immune organs in the upper respiratory tract and are known
induction sites for immunity against a number of respiratory
pathogens. The exposure to a large number of microbial antigens
results in a substantial number of proinflammatory T cells in NALT
which could potentially lead to a highly inflammatory response in
the presence of SAg-Sau.10 It is therefore important to understand
how SAg-Sau-driven inflammation is controlled in the distinct
immune environment of NALT, to better inform new strategies in
the management of SAg-Sau associated inflammatory diseases.
Staphylococcal superantigens mainly trigger Th1 and Th17
responses characterized by massive production of pro-
inflammatory cytokines, such as IFNγ, IL-17A, and TNF-α.11 IFNγ-
producing Th1 cells were initially thought to play a central role in
inflammatory/autoimmune diseases.12 However, subsequent find-
ings showed genetic depletion of IFNγ in murine models of
experimental autoimmune encephalomyelitis (EAE) enhanced
disease severity and that would argue against this hypothesis.13
Accumulating evidences support a more central role for Th17 cells
in mediating inflammatory/autoimmune diseases.14 By inducing
neutrophil influx and enhancing production of a wide spectrum of
inflammatory cytokines and chemokines, activation of Th17 cells
promotes clearance of microbes, but also causes inflammation-
driven tissue damage.14,15 Nasal carriage of SAg-Sau has been
linked to WG, MS and rheumatoid arthritis (RA), and Th17 cells are
known to play a critical role in the development of those
diseases.3,9,16–18 Tight regulation of Th17 activation is needed to
control the development of inflammatory/autoimmune diseases
associated with SAg-Sau infection.
Foxp3+CD25+Tregs are the major CD4+ T cell population
regulating over-activated inflammatory responses and maintain-
ing immune tolerance.19 Staphylococcal superantigens have been
shown to expand Foxp3+ Tregs in human PBMCs.20,21 However,
whether SAg-Sau-activated proinflammatory T cell responses are
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controlled by Tregs is debated.21,22 IL-10 is a well-established
immune suppressive cytokine produced by a number of immune
cells including Foxp3+ Tregs and Foxp3− type 1 regulatory cells
(Tr1).23 A recent study demonstrates that mice infected with Sau
exhibit enhanced IL-10 production which in turn inhibits the Th17
differentiation and therefore permits Sau systemic reinfection.24
While IL-10 is able to inhibit Th17 differentiation induced by Sau,
the role of IL-10 in regulating Sau-activated memory Th17
responses is unclear.
IL-35 is a member of the IL-12 cytokine family, which is made of
two shared subunits, IL-12A and EBI3.25 Unlike most of the other
pro-inflammatory cytokines in the IL-12 family, IL-35 has been
shown to suppress Th17 cell activation in animal models of
autoimmune/inflammatory disorders.25–27 Inducible IL-35-
producing regulatory T cells (iTr35s) have been identified, showing
potent regulatory control over effector T cells.26 To date, whether
IL-35 plays a role in Sau-activated pro-inflammatory T cell
responses has not been reported.
Here, we show SAg-Sau-activated Th17 responses in human
NALT were not suppressed by Foxp3+ Tregs and IL-10. SAg-Sau
stimulation significantly downregulated IL-35 expression in the
tonsillar CD4+ T cells, and exogenous IL-35 suppressed highly
activated Th17 responses elicited by SAg-Sau. Our results support
a critical role of IL-35 in suppressing SAg-Sau-driven inflammatory
Th17 responses.
RESULTS
SAg-Sau activates a potent Th17 response in human tonsillar
MNCs
To examine whether SAg-Sau activates Th17 responses in human
NALT, tonsillar mononuclear cells (MNCs) were stimulated with
bacterial culture supernatant of Sau. A potent Th17 response was
detected in tonsillar MNCs following stimulation with SAg-Sau
(Fig. 1a). The Non-Superantigenic Sau (NonSAg-Sau) strain also
activated a Th17 response, although significantly less than SAg-
Sau stimulation (Fig. 1a). A dose-dependent Th17 response was
shown following both NonSAg-Sau and SAg-Sau stimulation
(Fig. 1b). Increased IL-17A production in the cell culture super-
natant following stimulation was confirmed by ELISA (Fig. 1c). We
then compared the Th17 responses activated by SAg-Sau with
other frequently identified bacterial colonizers in the nasopharynx.
Streptococcus pneumoniae (Spn) elicited a weak Th17 response,
and no significant Th17 response was activated by M. catarrhalis
and coagulase-negative staphylococcal strains (Fig. 1d). To further
examine whether SAg-Sau carriage isolates from the nasopharynx
also activated strong Th17 responses, total enterotoxin A-E level in
the bacterial culture supernatant from Sau carriage isolates C1, C2
and C3 were measured by ELISA, and Th17 responses activated by
these carriage strains were examined. C3 strain, which contained a
similar level of enterotoxins as SAg-Sau, also activated a strong
Th17 response, higher than NonSAg-Sau. C1 and C2 produced low
level of enterotoxin A-E and activated Th17 response to a similar
extent as NonSAg-Sau (Fig. 1e, f). Compared to C3, both C1 and C2
appeared to activate a lower Th17 response although it did not
reach significance for C1 (Fig. 1e). Our data suggest Sau,
particularly superantigenic strains, can activate potent Th17
responses in human NALT.
SAg-Sau-activated Th17 responses are not suppressed by Foxp3+
Tregs
An Enhanced Th17 activation is usually accompanied with
decreased Foxp3+ Tregs.28 However, staphylococcal superanti-
gens have been shown to expand Foxp3+ Tregs in human
PBMCs.20,21 We examined whether SAg-Sau stimulation affected
Treg cell population in human NALT. Consistent with the
superantigenic effects in human PBMCs, SAg-Sau stimulation led
to expansion of the Foxp3+ Treg population, and this was
significantly stronger compared to NonSAg-Sau and Spn (Fig. 2a,
Supplementary Fig. 1a). Interestingly, IL-17A expression was
increased markedly in the expanded Foxp3+ Tregs (Fig. 2a,
Supplementary Fig. 1c), suggesting an unconventional Foxp3+
Treg population was induced in human NALT by SAg-Sau
stimulation.
Spn-activated Tregs have been previously shown to be highly
suppressive of T cell response.29 To determine whether SAg-Sau-
expanded Tregs are functionally competent, the suppressive effect
of Foxp3+ Tregs was then examined by assessing CD4+ T cell
proliferative response in tonsillar MNCs with or without Foxp3+
Tregs. By depleting CD25+ cells, over 95% of Foxp3+ Tregs were
removed from the MNCs (Supplementary Fig. 2a). Foxp3+ Treg-
depleted MNCs and unfractionated MNCs were stained with CFSE
and stimulated with SAg-Sau and Spn-TIGR4, respectively. CD4+
T cell proliferation was enhanced in Treg-depleted MNCs compared
to unfractionated MNCs following Spn-TIGR4 stimulation, however
SAg-Sau-activated CD4+ T cell proliferation was not affected by
Treg removal (Fig. 2b). These results suggest an impaired
suppression in NALT CD4+ T cell activation despite a highly
expanded Foxp3+ T cell population, however this phenomenon
appears to be specific to SAg-Sau.
Intriguingly, upon examining Th1 and Th17 responses, Treg
depletion resulted in higher numbers of IFNγ+CD4+ Th1 cells but
fewer IL-17A+CD4+ Th17 cells as compared to unfractionated
MNCs upon SAg-Sau stimulation (Fig. 2c, d). Further examination
revealed Treg depletion has resulted in the reduction of IL-
17A+Foxp3+ T cells following stimulation. However, the propor-
tion of IL-17A+Foxp3− T cells were not affected by Treg
removal (Supplementary Fig. 2b). Increased IFNγ (mean
increase: 3830.2 pg/ml) and decreased IL-17A (mean decrease:
585.2 pg/ml) concentrations were also detected in the culture
supernatant of Treg-depleted MNCs (n= 3, p < 0.05). Overall, the
findings indicate that tonsillar Foxp3+ Tregs are able to suppress
the Th1 activation but are unable to control the Th17 activation
elicited by SAg-Sau.
To determine whether this observation was distinct to the
nasopharynx immune microenvironment, we further examined
the regulatory role of Foxp3+ Tregs in peripheral blood mono-
nuclear cells (PBMCs). Consistent with the findings obtained from
tonsillar MNCs, Treg depletion in PBMCs also enhanced Th1, but
reduced Th17 response upon SAg-Sau stimulation (Supplementary
Fig. 3). Thus, despite their critical role in maintaining immune
tolerance, Foxp3+ Tregs were unable to inhibit SAg-Sau-activated
Th17 responses in humans.
SAg-Sau stimulation upregulates IL-10 but downregulates IL-35
expression in human tonsillar CD4+ T cells
Sau infection has been shown to promote IL-10 production, but
whether it alters IL-35 expression in CD4+ T cells is unknown.24
Expressions of IL-10 and IL-35 in tonsillar CD4+ T cells in response
to SAg-Sau stimulation were examined. IL-10 expression in CD4+
T cells, primarily within Foxp3− Tr1 cells, was significantly
increased following SAg-Sau stimulation, and this was consistent
with increased production of IL-10 in culture supernatants of
stimulated MNCs as measured by ELISA (Fig. 3a–c). IL-35 is a
heterodimeric cytokine consisting of IL12A and EBI3 subunits.
Both subunits were detected by RT-qPCR and Western Blot in
isolated CD4+ T cell with or without SAg-Sau stimulation and the
existence of IL-35 heterodimer was confirmed using co-
immunoprecipitation (Co-IP). The EBI3 subunit showed a slight
downregulation at mRNA level. However, IL12A expression was
substantially reduced at both mRNA and protein level, which
resulted in downregulated production of IL-35 heterodimer in
SAg-Sau-stimulated tonsillar CD4+ T cells (Fig. 3d–g). These results
indicate SAg-Sau stimulation has opposite effect on IL-10
(enhanced) and IL-35 (reduced) production in human tonsillar
CD4+ T cells.
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IL-10 suppresses SAg-Sau-activated Th1 response but not the Th17
response
The upregulated IL-10 expression in tonsillar MNCs following SAg-
Sau stimulation may be a self-regulatory mechanism to suppress
the highly inflammatory response that presides. By neutralizing IL-
10 produced in the culture supernatant, the regulatory effects of
IL-10 on both Th1 and Th17 activation were examined. Following
IL-10 neutralization, the number of IFNγ-producing Th1 cells was
increased in SAg-Sau stimulated tonsillar MNCs, however the
proportion of IL-17A-producing Th17 cells was unchanged (Fig. 4a,
b). This suggests that despite upregulated IL-10, Tr1 cells could not
suppress SAg-Sau-activated Th17 response. IL-10 mediated
regulation of Th1 and Th17 responses was further examined by
adding recombinant IL-10 to MNCs stimulated with SAg-Sau.
Again, addition of IL-10 suppressed Th1 activation (Supplementary
Fig. 4), and in fact enhanced SAg-Sau-activated Th17 responses
(Fig. 4c). The Th1 and Th17 cell populations were then divided into
IL-17A+IFNγ−, IL-17A+IFNγ+, and IL-17A−IFNγ+ subpopulations to
further define the opposing roles of IL-10 on regulation of IFNγ
and IL-17A expression in SAg-Sau-activated CD4+ T cells. IL-
17A−IFNγ+ cells were significantly reduced, and IL-17A+IFNγ+
cells were also decreased although this did not reach significance.
However, a marked increase in IL-17A+IFNγ− cell population was
observed in IL-10-treated cells, providing further evidence that IL-
10 could promote IL-17A expression in SAg-Sau-activated tonsillar
CD4+ T cells (Fig. 4d).
IL-35 suppresses over-reactive Th17 responses in SAg-Sau
stimulated tonsillar MNCs
The degree of Th17 activation elicited by SAg-Sau in tonsillar
MNCs varied from 2 to 10-fold among the individuals recruited in
our study (Fig. 5a). To determine whether IL-35 downregulation in
tonsillar CD4+ T cells by SAg-Sau was contributing to the highly
activated Th17 responses, tonsillar MNCs were stimulated with
SAg-Sau in the presence/absence of recombinant IL-35. Interest-
ingly, the percentage of IL-35-mediated Th17 suppression was
shown to be positively correlated with the level of Th17 activation
(Fig. 5a). Tonsillar samples were then divided into high responders
(≥ 5-fold increase) and low responders (<5-fold increase) based on
the average fold increase in the proportion of Th17 cells within
SAg-Sau-activated CD4+ T cell population. As shown in Fig. 5b,
addition of IL-35 significantly reduced Th17 activation in the high
responder group, whereas there was no effect on the low
responders. Consistent with this, IL-17A production was also
decreased in culture supernatants of high responders following IL-
35 treatment (Fig. 5c). In contrast to IL-10, IL-35 suppressed the IL-
17A+IFNγ− cells without affecting the IL-17A−IFNγ+ CD4+ T cell
population (Fig. 5d). These results suggest that IL-35 is able to
suppress over-reactive Th17 responses while maintaining a low
level of Th17 activation required for host defense in the human
NALT.
The recombinant IL-35 used for the above experiments was an
Fc fusion protein with linked EBI3 and IL-12A, which is widely used
to study the biological function of IL-35.25,30,31 Although an Fc
control protein was used at all times to exclude possible biological
effects from the human IgG1 Fc protein region included in the
recombinant protein and Fc treatment per se did not show any
effect on SAg-Sau-activated T cell responses (data not shown), the
way that protein subunits were fused together may also have
impact on the biological activity of recombinant IL-35. To confirm
that IL-35 mediated suppression of SAg-Sau activated Th17
response in tonsillar MNCs was not due to artificial IL-35-Fc fusion
protein, a transfected CHO cell line producing native form of IL-35
was constructed by introducing IL-12A and EBI3 expressing
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Fig. 1 SAg-Sau activates a potent Th17 response in human tonsillar MNCs. a, b, d, e Intracellular cytokine analysis of IL-17A-expressing
CD4+ T cells (Th17) in isolated human tonsillar MNCs 48 h following bacterial CCS (1 µg/ml) stimulation, compared to media control (MC)
MNCs. a Dot plots were gated on CD4+ T cells and numbers in the top right quadrants indicate the percentage of Th17 cells within the CD4+ T
cell population. Data were analyzed using paired t-test and displayed in mean ± SEM, n= 10. b Dose-dependent Th17 responses activated by
NonSAg-Sau and SAg-Sau, respectively. Results are representative of 3 individual samples. c IL-17A concentration in tonsillar MNCs culture
supernatants were measured by ELISA and samples assayed in duplicates. Data displayed is individual data points with mean ± SEM, n= 10.
Paired t-test was performed on log-transformed data. d Box and Whiskers plot showing the percentage of Th17 cells within CD4+ T cells in
tonsillar MNCs stimulated with Spn, M. catarrhalis, coagulase-negative staphylococcus (CNS, C4 and C5) and SAg-Sau, respectively. e The
percentage of Th17 cells within CD4+ T cell population was summarized for tonsillar MNCs activated by NonSAg-Sau, SAg-Sau, and Sau
carriage strains (C1, C2, and C3). Data (d, e) was displayed in median (center line), upper and lower quartiles (box limits) and minimum to
maximum range (whiskers). 8 (d) and 5 (e) individual samples were tested and analyzed. f Staphylococcal enterotoxin A-E level in Sau strains
(PC, positive control. NC, negative control), test was performed in duplicate. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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plasmids into CHO cells, respectively. Both IL-12A and EBI3
proteins were expressed in 4 transfected CHO cell colonies
selected (C7, C8, C14, and C15), and heterodimeric IL-12A/EBI3
protein secretion was confirmed by Co-IP Western Blot (Supple-
mentary Fig. 5). The conditioned medium generated by C7 CHO
cells, which produced the highest amount of IL-35 heterodimer,
was used to examine the suppressive activity of native IL-35 on
SAg-Sau-stimulated Th17 response. Tonsillar MNCs were cultured
in medium containing C7 CHO cell or control CHO cell conditioned
medium (either 1, 2, or 10%) and stimulated with SAg-Sau. MNCs
stimulated without conditioned medium was used as stimulation
control to calculate the suppression of Th17 responses by IL-
35_CHO or control CHO cell conditioned medium. The native IL-35
showed inhibition of SAg-Sau-activated Th17 proliferation in a
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Fig. 2 SAg-Sau-activated Th17 responses are not suppressed by Foxp3+ Tregs. a Analysis of Treg expansion and IL-17A-expressing Tregs in
isolated human tonsillar MNCs 48 h following bacterial CCS (1 µg/ml) stimulation. Dot plots were gated on CD4+ T cells and numbers in
bottom right and top right quadrants indicate the percentage of IL-17A− Foxp3+ and IL-17A+ Foxp3+ cells, respectively, within the CD4+ T cell
population. Data is displayed as mean ± SEM by column bar graphs and analyzed using paired t-test, n= 10. b Unfractionated MNCs and
CD25+ cell depleted MNCs were labeled with CFSE in order to quantify CD4+ T cell proliferation 5 days after SAg-Sau CCS (1 µg/ml)
stimulation. Histogram plots were gated on CD4+ T cells showing the median fluorescent intensity (MFI) of CFSE and numbers in the top left
corners indicate percentage of proliferated CD4+ T cells. Data points with mean ± SEM are shown in the dot plot on the right with 3 individual
samples tested. c, d IL-17A and IFNγ expression after 48 h of SAg-Sau CCS (1 µg/ml) stimulation for unfractionated MNCs and CD25+ cell
depleted MNCs. Results were summarized from 3 individual samples. c Zebra plots were gated on lymphocytes and numbers in top left and
right quadrants indicate the percentage of IFNγ+ CD4− lymphocytes and IFNγ+ CD4+ T cells (Th1) in total lymphocytes, respectively. d Zebra
plots were gated on CD4+ T cells, with the percentage of Th17 cells in CD4+ T cell population shown in the top right quadrants. Data were
analyzed using paired t-test. (ns: not significant).
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dose-dependent manner (Fig. 5e, f). Thus, it was confirmed that
both IL-35-Fc and native form of IL-35 were functionally capable of
regulating SAg-Sau-activated Th17 response in human tonsillar
MNCs. Recombinant IL-35 with Fc fusion was used for subsequent
experiments.
IL-35 downregulates SAg-Sau-induced RORγt expression in human
tonsillar CD4+ T cells
IL-35 has been reported to suppress Th17 cell differentiation.32 We
therefore examined the effect of IL-35 on SAg-Sau-induced Th17
differentiation from naïve tonsillar CD4+ T cells. CD45RO+ cell
depletion was performed to remove memory CD4+ T cells from
tonsillar MNCs, and the depleted MNCs were then stimulated with
SAg-Sau in the presence of Th17 polarizing cytokines (IL-1β, IL-21
and TGFβ1) for 7 days either with Fc control protein or IL-35. Fc
treatment did not affect T cell responses in CD45RO+ cell
depleted-MNCs following SAg-Sau stimulation. SAg-Sau-induced
IL-17A production was significantly reduced by the addition of IL-
35 (Fig. 6a). The expression of RORγt, the key transcription factor
controlling differentiation of Th17 cells,33 was also downregulated
by IL-35 in SAg-Sau-stimulated CD4+ T cells (Fig. 6b), suggesting
that IL-35 could suppress SAg-Sau-induced Th17 differentiation via
direct inhibition of RORγt expression.
SAg-Sau colonization of mouse nasopharynx induces IL-17A
expression and downregulates IL-12A in the cervical lymph node
CD4+ T cells
As we had shown a highly activated Th17 response in human
tonsillar MNCs driven by SAg-Sau, which was associated with
downregulated IL-35 expression in the CD4+ T cells in vitro, a
mouse nasal colonization model was used to further examine the
in vivo activation of NALT CD4+ T cells. C57BL/6 mice were
intranasally infected with SAg-Sau and Th17 response in cervical
lymph nodes (CLN) was assessed after secondary infection. All
mice infected with SAg-Sau carried the bacterium at 24 h post-
secondary infection (Fig. 7a). Consistent with in vitro Th17
activation by SAg-Sau in human tonsillar MNCs, mice infected
with SAg-Sau also had significantly higher Il17a mRNA expression
in their CLN CD4+ T cells compared to their naïve counterparts
(Fig. 7b). The mRNA expression of Il12a and Ebi3 were also
determined. Although less significant than in human tonsillar
CD4+ T cells, the expression of Il12a in mouse CLN CD4+ T cells
was also reduced by SAg-Sau colonization, while Ebi3 expression
remained unchanged (Fig. 7c, d). In humans, IL-35 is produced
primarily by effector CD4+ T cells, however in mice, Foxp3+ Tregs
constitutively express IL-35 and are the primary source of this
cytokine.34,35 SAg-Sau stimulation led to a more significant
decrease in IL-35 expression in human CD4+ T cells, suggesting
that it may primarily downregulate IL-35 expression in effector
CD4+ T cells. Despite this, both ex vivo human cell culture and
in vivo mouse carriage models show that SAg-Sau colonization
downregulates IL-35 expression in CD4+ T cells, which could
contribute to an enhanced Th17 response.
DISCUSSION
The balance between regulatory and pro-inflammatory host T cell
responses to SAg-Sau infection is likely to be critical in preventing
excessive inflammation (e.g., toxic shock) and autoimmune
conditions. Our study highlights a critical cellular regulatory
mechanism on Th17 activation in human nasopharynx mucosal
tissue, whereby IL-35 is identified as a key suppressive cytokine in
controlling SAg-Sau-driven inflammatory Th17 responses.
Although SAg-Sau induced a marked Treg expansion and
enhanced IL-10 production (Figs. 2a and 3a-c), they failed to
suppress SAg-Sau-activated Th17 responses. By contrast, IL-35
expression in tonsillar CD4+ T cells was markedly downregulated
by SAg-Sau which was associated with an enhanced Th17
Fig. 3 SAg-Sau stimulation upregulates IL-10 but downregulates IL-35 expression in human tonsillar CD4+ T cells. a IL-10 expression in
tonsillar lymphocytes 48 h following SAg-Sau stimulation. Representative dot plots with numbers in top left and right quadrants indicate the
percentage of IL-10+ CD4− and IL-10+ CD4+ T cells within total lymphocyte population. Results from 8 individual samples were analyzed and
summarized in the bar chat. b Bar chart showing the percentage of IL-10+ cells within Foxp3+ CD4+ T cell and Foxp3− CD4+ T cell
populations, respectively, n= 3. c IL-10 concentration in the culture supernatant of 48 h-cultured MNCs either unstimulated (MC) or stimulated
with SAg-Sau. Samples were measured by ELISA in duplicate, n= 7. d, e Tonsillar MNCs were stimulated with SAg-Sau CCS for 24 h following
which CD4+ T cell isolation was performed. mRNA was extracted from isolated CD4+ T cells for RT-qPCR. The fold change in Il12a (d) and Ebi3
(e) mRNA expression compared to the media control (MC) are shown. Tests were performed in duplicate, n= 4. f, g Tonsillar MNCs were
stimulated with SAg-Sau for 48 h and treated with brefeldin A for 4 h before harvesting cells for CD4+ T cell isolation. f Protein expression of IL-
12A and EBI3 subunits in isolated CD4+ T cells. g CD4+ T cell lysate was immunoprecipitated with anti-IL-12A and blotted with anti-EBI3 to
detect the expression of IL-35 heterodimer in CD4+ T cells. The blot image (f, g) are representative of 3 independent experiments. Data (a, b,
c, d, e) were analyzed using paired t-test.
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activation, and introduction of recombinant IL-35 suppressed the
Th17 response. These findings suggest IL-35, but not Foxp3+ Treg
or IL-10, is critical in suppressing SAg-Sau-activated inflammatory
Th17 response in human NALT.
We demonstrate SAg-Sau activated a potent Th17 response in
NALT, which is consistent with previous findings showing Sau
superantigens activate Th17 cells.11,36 Nevertheless, non-SAg-Sau
strains were also shown to activate a Th17 response, although in
general significantly less than SAg-Sau strains. It is possible that
some non-superantigenic Sau properties could also contribute to
Th17 activation.
Tregs in human PBMCs have been shown to suppress
proliferation of CD25−CD4+ T cells activated by anti-CD3 but
were unable to suppress staphylococcal superantigen-induced T
cell proliferation.21 Consistent with this finding, we show NALT-
derived Tregs failed to suppress SAg-Sau-activated proliferative
response. Interestingly, further examination revealed that Tregs
effectively suppressed IFNγ-producing Th1 cells but were unable
to control the activation of IL-17A-producing Th17 cells. SAg-Sau-
expanded Tregs exhibited markedly decreased expression of CD39
(Supplementary Fig. 6), which is an ectonucleotidase converting
extracellular ATP to suppressive adenosine with the help of
CD73.37 Both CD39+ and CD39− Tregs were shown to inhibit Th1
response but only CD39+ Tregs were capable of suppressing Th17
response in human PBMCs.38 The lack of CD39+ Tregs following
SAg-Sau stimulation may help explain the Treg-mediated differ-
ential suppression of Th1 and Th17 responses shown in our study.
In addition to expanded Foxp3+ Tregs, SAg-Sau also upregu-
lated IL-10 expression mostly by Foxp3− CD4+ T cells (Tr1) in
tonsillar MNCs (Fig. 3a, b). An intriguing finding in our study was
that SAg-Sau-activated Th17 cells were resistant to IL-10-mediated
suppression, while Th1 cells remained sensitive. IL-10/IL-10R
signaling in Tregs and Th17 cells has been reported to mediate
suppression of inflammatory Th17 activation.39,40 SAg-Sau stimu-
lation may impair the IL-10 signaling in activated Th17 cells
making them unresponsive to IL-10-mediated suppression.
More intriguingly, we demonstrate that the addition of
recombinant IL-10 further promoted IL-17A expression in
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Fig. 5 IL-35 suppresses over-reactive Th17 responses in SAg-Sau stimulated tonsillar MNCs. a–c Tonsillar MNCs were stimulated with SAg-
Sau CCS for 48 h with 100 ng/ml of recombinant IL-35 or Fc control protein. a The association between fold increase in Th17 proportion and
Th17 inhibition by IL-35. Each dot represents an individual sample, n= 22. Data was analyzed using linear regression. b The proportion of
Th17 cells in total CD4+ T cells is shown as fold increase against media control (MC). The line plot shows the suppressive effect of IL-35
on Th17 responses in high responder group (≥5-fold) and low responder group (<5-fold), respectively, n= 8 per group. c IL-17A concentration
in MNC culture supernatant of the high responders (n= 8) measured by ELISA, tests were performed in duplicate. d Inhibition of SAg-Sau
activated Th17 and Th1 responses by IL-35 or IL-10 in tonsillar MNCs. Zebra plots were gated on CD4+ T cells and numbers in top left and
bottom right quadrants indicate the percentage of IL-17A+ IFNγ− and IL-17A− IFNγ+ cells respectively in CD4+ T cell population. Data of 5
individual samples was analyzed using paired t-test and summarized in bar chats. e, f Tonsillar MNCs were stimulated with SAg-Sau (1 µg/ml)
in the presence of conditioned medium from IL-35-transfected CHO cells (Clone 7) or control CHO cells at 1, 2, and 10% respectively.
Five individual samples were tested and analyzed. e Representative dot plots were gated on CD4+ T cells and numbers in top right quadrants
indicate the percentage of IL-17A+ Ki67+ cells (Proliferating Th17 cells) in CD4+ T cells. f Suppression (%) of Th17 proliferation in IL-35-
transfected CHO cell medium-treated or control CHO cell medium-treated MNCs was calculated against stimulated MNCs without CHO cell
medium, mean ± SEM is shown.
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SAg-Sau-stimulated tonsillar CD4+ T cells. It is plausible that
plasticity of Th17 leads to the generation of an IL-17A+IFNγ+
(Th17/Th1) cell subset, this may be associated with an enhanced
STAT1 activation in the cells which limits STAT3 activity and its
downstream IL-17 expression. If STAT1 signaling keeps pushing
over and perturbs the delicate balance of STAT1 and STAT3 in
the Th17/Th1 cells, these cells may lose expression of Th17-
related genes and become ex-Th17 cells.41 However, inhibiting
STAT1 activation could remove its suppression over STAT3 and
thereby revive Th17 effector phenotype.42 Hence, in SAg-Sau-
stimulated MNC, exogenous IL-10 may promote IL-17A expres-
sion in Th17/Th1 and ex-Th17 subsets through downregulating
IFNγ and STAT1 activation, thus leading to an enhanced IL-
17A+IFNγ-, but a reduced IL-17A+IFNγ+ cell subset.
Neither Foxp3+ Tregs nor IL-10 was able to control SAg-Sau-
activated potent Th17 responses. This led us to examine the role of
another regulatory cytokine, IL-35, which has been shown to inhibit
autoimmunity by suppressing inflammatory Th17 activation in
murine studies.25,35,43,44 We show IL-35 heterodimer was expressed
in human tonsillar CD4+ T cell without stimulation and its expression
was significantly downregulated upon SAg-Sau stimulation. This
raised the possibility that loss of IL-35 expression may contribute to
the strong Th17 response activated by SAg-Sau. Indeed, addition of
IL-35 suppressed SAg-Sau-activated Th17 responses which positively
correlated with the level of Th17 activation (Fig. 5a). Depending on
the closeness between IL-35-producing cells and Th17 cells, the
biological concentration of IL-35 in physiological condition to inhibit
Th17 cells could be hard to determine. The concentration of
recombinant IL-35 we used to treat cells was carefully titrated based
on published IL-35 studies.25,43 The finding that recombinant IL-35
selectively suppressed those with high Th17 responses following
SAg-Sau stimulation suggests IL-35 may regulate physiological Th17
activation and potentially pathogenic Th17 activation through
different signaling pathways.
IL-10-dependent and Treg-dependent mechanisms have been
reported to play a role in IL-35-mediated Th17 suppression.45,46
We have shown that IL-10-mediated and Treg-mediated suppres-
sion on effector Th17 cells were impaired by SAg-Sau stimulation,
which may explain why IL-35 did not suppress SAg-Sau-activated
low Th17 responses. IL-35 could signal through a unique IL-12Rβ2:
gp130 heterodimer or via homodimers to suppress effector T cell
activation, but only via the heterodimeric receptor can it induce
expression of IL-35.47 It is possible that IL-35-mediated
Th17 suppression require high expression of IL-12Rβ2:gp130
heterodimer and through induction of IL-35 in targeted Th17 cells.
Similar to IL-10 expression in Th17 cells, which directs the cell
towards a regulatory phenotype,48 IL-35 expression in pathogenic
Th17 cells may also elicit an anti-inflammatory gene expression
profile to reverse the post-activation fate of pathogenicity.
In conclusion, we identify IL-35, but not IL-10, as a critical cytokine
in controlling SAg-Sau-activated Th17 responses in human naso-
pharynx. This finding may also apply to other mucosal and systemic
compartments where SAg-Sau or superantigens could cause Th17-
mediated inflammation. The results may have therapeutic implica-
tions for IL-35 in future management of SAg-Sau-induced inflam-
matory disease (e.g., toxic shock) or autoimmune conditions.
METHODS
Patients and samples
The adenotonsillar tissues were obtained from immunocompetent
patients undergoing adenoidectomy and/or tonsillectomy due to
upper-airway obstructions at Alder Hey children’s Hospital, and
Royal Liverpool and Broadgreen University Hospitals. Patients with
known immunodeficiency or who had been prescribed antibiotics
within 3 weeks before surgery were excluded. Nasopharyngeal
swabs were taken on the day of operation and stored in STGG
a b
Fig. 6 IL-35 downregulates SAg-Sau induced RORγt expression in
human tonsillar CD4+ T cells. CD45RO+ cell depleted tonsillar
MNCs were stimulated with SAg-Sau CCS (50 ng/ml) for 7 days in the
presence of recombinant IL-1β (50 ng/ml), IL-21 (50 ng/ml), and
TGFβ1 (2 ng/ml). 10 ng/ml of recombinant IL-35 or Fc control protein
were added at day 0 and day 3. a IL-17A concentration in the cell
culture supernatants as measured by ELISA, tests were performed in
duplicate. Results of 6 individual samples were analyzed using
paired t-test. b Line plot showing the percentage of RORγt+ CD4−
lymphocytes and RORγt+ CD4+ T cells in SAg-Sau stimulated
tonsillar MNCs with or without IL-35. Data is shown in mean ± SEM,
n= 4.
a b
c d
Fig. 7 SAg-Sau colonization of the mouse nasopharynx induces
IL-17A expression and downregulates IL-12A in the cervical lymph
node CD4+ T cells. C57BL/6 mice were infected intranasally
with 107 CFU of SAg-Sau at day 0 and day 14, respectively.
Nasopharynx and cervical lymph nodes (CLN) were harvested at
24 h post secondary infection. a Nasopharyngeal homogenates
were plated on blood agar plates and colonies were counted after
overnight culture. b–d CLN from 3 mice were pooled for
lymphocyte isolation and CD4+ T cell separation. mRNA was
extracted from separated CD4+ T cells for RT-qPCR. The mRNA
expression of Il17a (b), Il12a (c), and Ebi3 (d) are shown as
fold changes against control mice. Results represent 2 indepen-
dent experiments, 9 mice per group were used in each
experiment. Data was analyzed using unpaired t-test and
displayed as mean ± SEM.
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medium at −80 °C before bacterial culture as described pre-
viously.49 The study was approved by the National Research Ethics
Committee and written consent was obtained in all cases. In total,
adenotonsillar tissue samples from 65 patients were used in
this study.
Mouse nasal colonization model
Female C57BL/6 mice aged 6–8 weeks were purchased from
Charles River, UK. Mice were maintained in individually ventilated
cages at 22 ± 1 °C and 65% humidity with a 12 h light-dark cycle.
Mice were infected intranasally with 107 colony-forming unit (CFU)
of SAg-Sau in 10 μl PBS or PBS only for control group mice. A
second dose of SAg-Sau was given at day 14 post primary
infection. Mice were then culled at 24 h post-secondary infection
to assess the nasopharyngeal bacteria load and CD4+ T cell
responses in the cervical lymph nodes (CLNs). All experimental
protocols were approved and performed in accordance with the
regulations of the Home Office Scientific Procedures Act (1986),
project licence P86De83DA and the University of Liverpool Ethical
and Animal Welfare Committee.
The nasopharyngeal tissue was removed and homogenized in
3 ml of sterile PBS before plating out on blood agar for assessment
of tissue CFU. Lymphocytes were isolated from the dissected CLN,
followed by CD4+ T cell separation using positive selection
microbeads (Miltenyi). RT-qPCR was performed with isolated CLN
CD4+ T cells (purity > 96%) to detect gene expression.
Preparation of bacterial culture supernatant
Pneumococcal strains used in this study were standard encapsu-
lated serotype 2 (D39) strain and virulent serotype 4 (TIGR4) strain.
For S. aureus, we included Superantigenic strain FRI913 (positive
for tsst, sea, sec, and see), Non-Superantigenic strain HIP07930
(negative for PVL, tsst, sea, seb, sec, sed and see) (BEI Resources)
and 3 carriage strains (Sau-C1, Sau-C2, and Sau-C3) isolated from
the nasopharyngeal swabs of subjects from this study. Strains of
M. catarrhalis and Coagulase-Negative Staphylococcus (CNS) (CNS-
C4 and CNS-C5) were also carriage isolates from the study
subjects. Bacteria were cultured in Todd-Hewitt broth (Oxoid,
Basingstoke, UK) supplemented with 0.5% yeast extract at 37 °C
until the OD620 reaches 0.5. Bacterial culture supernatant was
prepared and concentrated as described previously.49 The protein
concentration of the concentrated culture supernatant (CCS) was
measured using PierceTM BCA Protein Assay Kit (Thermo Fisher
Scientific). The RIDASCREEN@ SET Total Kit (r-biopharm, Germany)
was used to detect total staphylococcal enterotoxin A-E level in
the culture supernatant of 3 carriage strains.
Human tonsillar mononuclear cell isolation, culture, and
stimulation
Tonsillar mononuclear cells (MNCs) were isolated using methods
described previously.49 Briefly, palatine tonsil was minced in Hank’s
buffer with a sterile scalpel before filtering through a 70 nm cell
strainer. MNCs were isolated by Ficoll density gradient centrifugation
(GE Healthcare). Cells were washed and suspended in RPMI1640
(Thermo Fisher Scientific) supplemented with 10% fetal bovine
serum (Sigma Aldrich), 2 mmol/L glutamine 100 U/ml penicillin and
100 μg/ml streptomyicin (Thermo Fisher Scientific). In some experi-
ments, CD69+, CD45RO+ cells or CD25+ cells were depleted from
the MNCs by magnetic cell sorting (Miltenyi Biotec, Surrey, UK)
according to the manufacturer’s instructions. Purity of isolated
CD69− MNCs (>95%), CD45RO− MNCs (>99%) and Treg-depleted
MNCs (>95%) following CD25+ cell depletion was confirmed by flow
cytometry. The tonsil MNCs were cultured at 4 × 106 cells/ml in 48-
well plate and stimulated with 1 μg/ml bacterial CCS for 48 h to
examine memory T cell responses. In IL-10 neutralization experi-
ment, cells were treated with 1 μg/ml of LEAF purified anti-human
IL-10 or rat IgG1κ isotype ctrl antibody (BioLegend). In some
experiments, 100 ng/ml of recombinant IL-10 and IL-35 were added
to the cell culture, respectively. CD45RO+ cell-depleted MNCs were
cultured in the presence of 2 ng/ml of TGF-β1, 50 ng/ml of IL-1β, and
50 ng/ml of IL-21 and stimulated with 50 ng/ml bacterial CCS for
7days to induce Th17 cell differentiation, with recombinant IL-35 or
Fc control protein being added at day 0 and day 3. Recombinant IL-
10 was purchased from PeproTech and other recombinant proteins
were from R&D systems.
Intracellular cytokine staining
Tonsillar MNCs were treated with Brefeldin A (eBiosciences) for 4 h
before harvesting cells in order to block cytokine secretion. MNCs
were stained with fluorescence labeled anti-human CD4, followed
by fixation and permeabilization and staining intracellularly with
fluorescence labeled anti-human Foxp3, IL-17A, IFNγ, IL-10, RORγt,
and Ki67 in different combinations. Stained cells were acquired on
BD Celesta or BD Canto II and data was analyzed by Flowjo. Anti-
human CD4-PECy7, IL-17A-Alexa Fluor 647, Foxp3-Alexa Fluor 488,
IL-10-PE, and RORγt-PE FACS antibodies were from BD Biosciences.
Other antibodies were purchased from BioLegend.
Quantitative reverse transcription polymerase chain reaction (RT-
qPCR)
Human tonsillar CD4+ T cells were isolated from 24 h stimulated
tonsillar MNCs by magnetic cell sorting with a purity of > 99%. 1 ×
106 isolated CD4+ T cells were used for total RNA extraction with
RNeasy kit (Qiagen) according to the manufacturer’s instructions.
cDNA was synthesized using Promega kit and qPCR was
performed using SYBR® Green JumpStartTM Taq ReadyMixTM
(Sigma) on Bio-Rad CFX96TM. Gene expression in mouse CLN
CD4+ T cells was also examined as described above. All qPCR
reactions were performed in duplicate.
Primers used for qPCR are displayed in Table 1. mRNA
expression levels were normalized to the levels of human or
mouse βactin housekeeping gene and calculated using 2-ddCT
formula.
Expression of recombinant human IL-35 in its native form in CHO
cell
Expression plasmids containing genes encoding human EBI3 (pRP-
Neo-hEBI3) and IL-12A (pRP-Puro-hIL12A) were constructed by
VectorBuilder. Plasmids were introduced into CHO cells using
Lipofectamine3000 (Invitrogen) cell transfection kit. Successful
transfectants were selected and expanded via G418 and
puromycin double selection. Co-expression of human EBI3 and
IL-12A in transfected clones was confirmed by Western blotting.
The heterodimeric EBI3/IL-12A (IL-35) secretion was detected by
co-immunoprecipitation and Western blotting. IL-35-expressing
CHO cell clones and control CHO cells were cultured in a
comparable cell density. The cell culture medium collected at 48 h
was used as conditioned medium to test the biological function of
native IL-35 in this study.
Immunoprecipitation and Western Blotting
Tonsillar MNCs were stimulated with Sau CCS for 48 h with the
addition of Brefeldin A for the last 4 h followed by isolation of
CD4+ T cells. For immunoprecipitation, equal number (1 × 107) of
isolated cells were lysed in 1 ml of RIPA buffer without SDS
(Sigma). The cell lysis was sonicated and centrifuged to remove
cell debris and DNA fragments before incubating with 1.5 μg/ml
anti-human IL-12A mouse monoclonal antibody (mAb) (R&D,
Clone 27537) at 4 °C for 1 h. 50 μl of buffer equilibrated Sheep
anti-Mouse IgG conjugated Dynabeads M-280 (Life Technology)
were added to the 1ml cell lysis and incubated overnight at 4 °C
to capture the target protein. Dynabeads were washed and
heated at 100 °C for 10 min to elute antibody captured protein in
reducing sample buffer. Protein samples were analyzed by
standard Western Blotting using 1 μg/ml anti-human EBI3
(Biolegend, Clone A15058A). For the detection of IL-12A and
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EBI3 separately in stimulated CD4+ T cells or constructed CHO cell
clones, standard Western Blotting was performed using above
mentioned anti-IL-12A and anti-human EBI3 mAbs, respectively.
Measurement of cytokine production
Tonsillar cell culture supernatant was collected following cell
culture with or without stimulation. IL-17A and IL-10 concentra-
tions in the culture supernatant were measured by ELISA kits
(eBioscences) following the manufacturer’s instructions. All
samples were tested in duplicate.
Statistical analysis
Data distribution were tested using D'Agostino-Pearson or
Shapiro-Wilk normality tests and results were then analyzed
accordingly with paired t-test (two-tailed) or unpaired t-test (two-
tailed). Data that is not normally distributed was log-transformed
before performing parametric t-tests or analyzed using Wilcoxon
matched-pairs signed rank test (two-tailed). The association
between fold-increase in Th17 response and Th17 inhibition by
IL-35 was analyzed using linear regression. All data was analyzed
in Prism 7 software. Data displayed is mean ± SEM for column bar
graphs and line plots. For data shown as box and whiskers,
median (center line), upper and lower quartile (box limits) and
minimum to maximum range (whiskers) are displayed. Asterisks
denote p-value (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
p-value < 0.05 were considered significant. n.s. means not
significant.
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